Zolgensma tumour risk: Novartis reports nine tumour cases, two with vector integration evidence. What the labels say and what is unknown.
Zolgensma Tumour Risk: Does the Gene Therapy Cause Tumours?
read more
Pharma
MariTide Approval: When Could Amgen’s Obesity Drug Reach Patients?
MariTide approval depends on Phase 3 data due in 2027. See what Amgen has disclosed, how the FDA review clock works and what comes next.
Pharma Q3 2026 Earnings: GLP-1s, the Keytruda Cliff and Vaccines
Eli Lilly began 2026 expecting revenue of $80bn to $83bn. After its third quarter, it now expects $91bn to $92bn. Lilly’s sales reached $24.4bn in the three months to September, up 39%. Most of its large peers grew in single digits. Read together, pharma Q3 2026...
Rethinking Biologics Plants to Earn Attractive Returns
The rapid growth of biologics and other advanced therapeutic modalities is transforming pharmaceutical R&D and manufacturing. From monoclonal antibodies and oligonucleotides to cell and gene therapies, these products introduce a level of process complexity,...
ObesityWeek 2026 Preview: The Data to Watch in Washington
ObesityWeek 2026 runs from 14 to 17 November in National Harbor, Maryland, just outside Washington. The meeting is The Obesity Society’s 44th annual gathering. Novo Nordisk arrives with 26 abstracts, including the first results from REDEFINE 9, its lower-dose...
ESMO 2026: The Five Results That Could Change Cancer Treatment
ESMO 2026 in five results: tarlatamab, an mRNA melanoma vaccine, divarasib, VOLGA and ivonescimab, plus the caveats that matter.
ESMO 2026: The Five Results That Could Change Cancer Treatment
ESMO 2026 closed in Madrid on 27 October after five days of practice-shaping data. The most closely watched results came in three Presidential Symposia, which carried twelve late-breaking phase 3 trials. Five of them stand out for their potential to change how...
Peptide Compounding Explained: What the HHS Six-Peptide Policy Allows
Peptide compounding in the United States has entered a new phase. The Department of Health and Human Services (HHS) will not act against compounders of six unapproved peptides, within strict conditions. The peptides are BPC-157, Epitalon, KPV, MOTS-c, Semax and...
Retatrutide vs Ozempic: How Do They Compare in Diabetes?
Retatrutide vs Ozempic now has a head-to-head answer in type 2 diabetes. In an 80-week phase 3 trial, retatrutide lowered A1C by 2.2 percentage points, against 1.8 for Ozempic 2 mg. Body weight fell by 19.5 to 20.9 per cent on retatrutide and 9.4 per cent on Ozempic....
Weight Is Not Composition: What Surgeons See After GLP-1 Weight Loss
The GLP-1 era has given clinicians something they have wanted for decades: medications that produce weight loss approaching what was once possible only with surgery. Semaglutide and tirzepatide routinely deliver reductions of 15% to 20% of body weight in trials, and...
What the Next Generation of GLP-1s Means for Pharmacists and Patients
GLP-1 receptor agonists (GLP-1 RAs) have reshaped the treatment of type 2 diabetes and obesity. But the next phase of GLP-1 therapy, and of incretin-based treatment more broadly, is likely to have implications that extend well beyond the approval of another...
Del-Desiran Next Steps: Will Novartis Continue After HARBOR?
Novartis has not yet said whether it will keep developing del-desiran, its drug for myotonic dystrophy type 1 (DM1). The del-desiran next steps depend on the full HARBOR dataset and on talks with regulators. On 27 October 2026, Novartis reported a USD 1.9 billion...
Psychobiotics and Depression: Exploring the Gut–Brain Connection
Depression care continues to evolve as researchers explore why people respond differently to treatment. One area drawing attention is the relationship between the gut microbiome and the brain. Could psychobiotics, which target this connection, offer additional support...
GLP-1s in Adolescents: What the Paediatric Obesity Evidence Shows
The case for GLP-1s in adolescents with obesity now rests on several randomised trials and two marketing authorisations. Real-world data are growing too. That evidence shows substantial reductions in body mass index over 56 to 68 weeks. It says much less about years...
Divarasib Approval: When Could Roche’s KRAS Inhibitor Reach Patients?
Divarasib approval has no confirmed date, but Roche’s own guidance points to 2027. Roche’s Pharma Day slides of 28 September 2026 list US and EU approval as a 2027 milestone. No regulatory filing for the KRAS G12C inhibitor had been announced in the sources reviewed...
Imdelltra Imfinzi Approval: When Could First-Line Use Begin?
Amgen and AstraZeneca presented full DeLLphi-305 results at the ESMO Congress in Madrid. The phase 3 trial added Amgen’s Imdelltra (tarlatamab-dlle) to AstraZeneca’s Imfinzi (durvalumab). It cut the risk of death by 58 per cent in extensive-stage small cell lung...
OOS Investigation: A Solubility-Related HPLC Assay Failure
A low out-of-specification (OOS) assay result does not always originate in the analytical laboratory. In pharmaceutical manufacturing, an OOS investigation must consider laboratory testing, raw material properties, manufacturing instructions and process execution...
Pharma’s Digital Maturity Divide Is Holding Back AI Adoption
AI is creating new opportunities across the pharmaceutical industry, but not every organisation is equally equipped to capitalise on them. The differentiator is not simply access to AI, but digital maturity; the strength of the infrastructure underpinning it. Those...